

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
 Shinichi HIROSE et al. : Attorney Docket No. 2006_1477A
 Serial No. 10/591,587 : Group Art Unit **Not Yet Assigned**
 Filed September 5, 2006 : Examiner **Not Yet Assigned**
 EPILEPSY MODEL ANIMAL (CHRNA4:S284L)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☐ each reference previously cited in the international application PCT/_____; and/or
- ☐ each reference previously cited in prior parent application Serial No. _____.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

THE COMMISSIONER IS AUTHORIZED
 TO CHARGE ANY DEFICIENCY IN THE
 FEES FOR THIS PAPER TO DEPOSIT
 ACCOUNT NO. 23-0975

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.H./

and thus no certification and/or fee is required.

- 1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) ☐ the certification of paragraph 2 below is provided, **or**
(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.


4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.
6. ☐ Statement Under 37 CFR 1.704(d)

Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart application, and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Shinichi HIROSE et al.

By



Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
December 4, 2006

Receipt date: 12/04/2006

10591587 - GAO:1633

Sheet 1 of 1

INFORMATION DISCLOSURE STATEMENT


FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: December 4, 2006

ATTY DOCKET NO.
2006_1477ASERIAL NO.
10/591,587APPLICANT
Shinichi HIROSE et al.FILING DATE
September 5, 2006

GROUP



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AG						
	AH						
	AI						
	AJ						
	AK						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

AL	R. Saito et al., "Characteristics of transgenic rats harboring a mutation underlying human autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)", J. Pharmacol. Sci., Vol. 23, No. 94, Suppl. I, p. 102, February 2004.
AM	S. Hirose et al., "A novel mutation of CHRNA4 responsible for autosomal dominant nocturnal frontal lobe epilepsy", Neurology, Vol. 53, No. 8, pp. 1749-1753, November 1999.
AN	A. Rozycka et al., "Evidence for S284L mutation of the CHRNA4 in a white family with autosomal dominant nocturnal frontal lobe epilepsy", Epilepsia, Vol. 44, No. 8, pp. 1113-1117, August 2003.
AO	N. Matsushima et al., "Mutation (Ser284Leu) of neuronal nicotinic acetylcholine receptor $\alpha 4$ subunit associated with frontal lobe epilepsy causes faster desensitization of the rat receptor expressed in oocytes", Epilepsy Research, Vol. 48, pp. 181-186, 2002.
AP	E. Tribollet et al., "Role of neuronal nicotinic receptors in the transmission of processing of information in neurons of the central nervous system", Pharmacology, Biochemistry and Behavior, Vol. 70, pp. 457-466, 2001.

EXAMINER

/Kelaginamane Hiriyanna/

DATE CONSIDERED

03/30/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy this form with next communication to applicant.

REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.H./